Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Patient adherence for successful tuberculosis treatment

Patient adherence for successful tuberculosis treatment

March 28, 2007

Nearly 2 million people die from tuberculosis each year, mainly in the poorest countries. The pathogen, Koch's bacillus, can pass easily by aerial infection from one individual to another. The spread of the disease, favoured by the Aids epidemic and the appearance of multi-resistant strains, has led WHO to make tuberculosis control one of the world's main health priorities. The existing treatment, which combines several antibiotics prescribed for a period of 6 to 8 months - as against 18 months to 2 years still only a few years ago - has proved efficient in 95 % of cases. However, this efficacy is called into question by the low adherence of patients to treatment, particularly in the most deprived areas, which are often indeed the worst hit by the disease. In spite of the WHO recommendation to administrate the treatment under the direct supervision of health care personnel who play the role of supporter (DOT : Directly observed therapy), more than 10% of patients stop the treatment before the prescribed period. This defaulting, along with irregularity in taking the medicines, creates increased risk of serious relapse, which opens the way to a rise in transmission events and the emergence of bacteria resistant to the prescribed antibiotics.

Starting from the principle that tuberculosis control must involve the identification of the obstacles to full comprehensive access to treatment, IRD researchers and their partners (1) studied, in Senegal, the different geographical, behavioural and socio-cultural factors that enter into the perception of the treatment and adherence to it.




In these countries, where over 9000 new cases of tuberculosis are diagnosed every year, access to free treatment is provided by the National Tuberculosis Control Programme through government health districts (2). However, nearly 30 % of patients do not follow this treatment correctly and scarcely 60% of people ill from the disease receiving a prescription manage to be cured. What are the reasons for this? Long distances from the health centres are among the first difficulties encountered. However, insufficient emphasis on listening to patients, counselling and information provision by health district personnel, associated with shortfalls in following up the DOT strategy also combine to discourage patients from taking the treatment right to the end of the prescribed course. In this context, the researchers looked simultaneously into the relations between health-care staff and the tuberculosis patients, the perception of the disease and its treatment in the community in which they live. They thus proposed action consisting of four major strands: training of health-care personnel, aiming to improve communication and support to patients, the decentralization of access to treatment to offer availability at local medical posts by involving health personnel who are attached to these, reinforcement of the DOT strategy by allowing patients to choose their supporter from among the staff or from within their community (imam, family relation, teacher"¦) and improved coordination of the activity of medical posts from the district centres.

To test the effectiveness of this action, a randomized controlled clinical trial was run between June 2003 and January 2005 on 16 district health centres and 1522 patients, who were separated at random into two groups. The first group was treated according to the action procedure proposed by the researchers, the second according to the usual strategy of the National Tuberculosis Control Programme (control group). After one year, a distinct improvement in adherence to treatment was observed in the first case: the rate of cure from tuberculosis rose by 20% and the proportion of patients defaulting fell by two-thirds (from 16.8 to 5.5 %).

The training of health-care personnel, communication to inform patients and make them aware of their responsibilities, just as the taking into account of the local, social and cultural context of communities, clearly appear to be essential factors for the sound running of the therapy and the long-term efficacy of actions geared to tuberculosis control. This action strategy, by improving adherence to treatment and the rate of successful patient outcomes, should thus help restrict the spread of the disease and prevent the arrival on the scene of new resistant strains of bacteria. Research work is continuing, in the form of a trial conducted by the IRD in conjunction with WHO, aiming to make available a shorter, 4-month treatment which could lead to still a further improvement of adherence and outcome results.

Institut de Recherche Pour le Développement



Related Tuberculosis Current Events and Tuberculosis News Articles Tuberculosis Current Events and Tuberculosis News RSS Tuberculosis Current Events and Tuberculosis News RSS
Researchers identify new leprosy bacterium
A new species of bacterium that causes leprosy has been identified through intensive genetic analysis of a pair of lethal infections, a research team reports in the December issue of the American Journal of Clinical Pathology.

Stopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.

First trachea transplant without immunosuppression
After 4 years of going from consultation to consultation, Claudia Castillo finally found a solution to her respiratory problems. The young Colombian woman suffered from a cough that took a long time to be diagnosed as tuberculosis.

Proteomics Study Yields Clues As To How Tuberculosis Might Be Thwarting The Immune System
A link between the immune system and the self-cleaning system by which biological cells rid themselves of obsolete or toxic parts may one day yield new weapons in the fight against tuberculosis and other deadly infectious diseases.

XDR-TB: Deadlier and more mysterious than ever
New research has found that XDR-TB is increasingly common and more deadly than previously known. Extensively drug-resistant tuberculosis (XDR-TB) is a growing public health threat that is only just beginning to be understood by medical and public health officials.

Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.

Parasites that live inside cells use loophole to thwart immune system
St. Jude Children's Research Hospital scientists have discovered a mechanism by which intracellular pathogens can shut down one of the body's key chemical weapons against them: nitric oxide.

Persistent bacterial infection exploits killing machinery of immune cells
A new study reveals an important and newly discovered pathway used by disease-causing bacteria to evade the host immune system and survive and grow within the very cells meant to destroy them. This discovery may lead to new treatments and vaccines for tuberculosis (TB) and certain other chronic bacterial and parasitic infections.

Health Care Barriers for Undocumented Immigrants: Raising Tuberculosis Risk?
A new study raises the question, do barriers to health care for undocumented immigrants increase the public health risk of tuberculosis? The study, published in the November 15, 2008 issue of Clinical Infectious Diseases and now available online, suggests that undocumented immigrants with tuberculosis have symptoms longer before seeking care than documented immigrants or U.S.-born patients, resulting in more severe symptoms and more opportunities for transmission.

UCLA develops safer, more effective TB vaccine for HIV-positive people
UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials.
More Tuberculosis Current Events and Tuberculosis News Articles


The Bioarchaeology of Tuberculosis: A Global View on a Reemerging Disease
by CHARLOTTE ROBERTS, JANE BUIKSTRA

Though apparently in decline during the first half of the 20th century, tuberculosis has reawakened in both developed and developing countries, particularly among susceptible populations with immunodeficiency disorders....



The Forgotten Plague: How the Battle Against Tuberculosis Was Won - And Lost
by Frank Ryan

Tuberculosis has claimed more than a billion lives worldwide. In this acclaimed book, Dr. Frank Ryan tells the remarkable story of the dedicated doctors, chemists, and bacteriologists who halted the course of this ferocious disease--until the "old enemy" found in AIDS a deadly ally to form a drug-resistant synergy. 8 pages of...



The White Plague: Tuberculosis, Man, and Society
by Rene J. Dubos



Tuberculosis (TUBERCULOSIS ( ROM))

This comprehensive clinical reference is edited by experts from the NYU-Bellevue Chest Service, which through its influence in tuberculosis care and education has been an integral part of the formation of the entire specialty of pulmonary medicine. The book draws on this extensive experience to present an authoritative account of the history, epidemiology, microbiology, immunology, clinical...

Tuberculosis (Deadly Diseases and Epidemics)
by Kim Renee Finer, I. Edward Alcamo

Experts in the field of microbiology tell the great "detective stories" of how some of the world's best-known deadly disease-causing microbes were first isolated, identified, and studied. Readers learn how these deadly viruses and bacteria cause disease and what steps have been taken to eradicate them. Tuberculosis killed one out of every seven people living in the United States and Europe in the...

Diagnostic Standards and Classification of Tuberculosis -
by National Tuberculosis and Respiratory Disease Association -

Clinician's Guide to Tuberculosis (Clinician's Guide to Tuberculosis (Iseman))
by Michael D. Iseman

Written by an eminent tuberculosis specialist from a premier medical institution, this volume is a practical clinical reference on tuberculosis. The major focus is on bedside care, including diagnosis, treatment, and patient management. The author clearly and concisely explains which treatments are most effective and addresses the problems of managing HIV-positive patients and drug-resistant...



Mycobacterium Tuberculosis - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
by ICON Health Publications

In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and...



Pulmonary Tuberculosis: Its Etiology, Symptomatology and Therapeutics
by David Jessup Doherty, Hugo Ziemssen



Tuberculosis (Twenty-First Century Medical Library)
by Diane Yancey

One of the deadliest diseases healthcare workers fight today, tuberculosis (often called TB) infects the lungs of one-third of the world's population and kills about 2 million people a year. While scientific breakthroughs brought this bacterial disease under control during the 1960s to the 1980s, it was never completely eliminated. In the early 1990s, TB came back as a serious global threat. Not...

© 2008 BrightSurf.com